Somaxon Pharma. Inc. v. Par Pharma. Inc., 11-0476 (D. Del.)
Somaxon Pharma. Inc. v. Mylan Inc., 11-0571 (D. Del.)
|
Silenor® (doxepin tablets)
|
7,915,307
6,211,229
|
Mylan will get exclusive right to start selling an authorized generic of Silenor in the U.S. on Jan. 1, 2020;
Mylan’s exclusivity is good for 180 days but may extended for up to 360 days;
Somaxon and Mylan also entered into a supply agreement;
In a separate agreement with Somaxon, Par will be able to start selling a generic version of Silenor 180 days after another generic version of Silenor is sold in the U.S. by a third party.
|
AstraZeneca Pharma LP v. Intellipharmaceutic Corp., 11-4498, 12-2855 (S.D.N.Y.)
|
Seroquel XR® (quetiapine fumerate extended-release tablets)
|
4,879,288
5,948,437
|
IPC shall not market its generic product until November 2016;
Patents-in-suit are valid and enforceable.
|
Pfizer Inc. v. Impax Labs., Inc., 08-2137 (D.N.J.)
|
Detrol® LA (tolterodine tartrate extended-release capsules)
|
5,382,600
6,630,162
6,770,295
|
N/A
|
Alza Corp. v. Impax Labs., Inc., 11-0395 (D. Del.)
|
Concerta® (methylphenidate hydrochloride extended-release tablets)
|
6,930,129
|
Impax may sell generic Concerta effective July 2014;
Impax’s settlement authorizes Teva to market Impax’s generic tablets.
|
Shire LLC v. Anchen Pharma., Inc., 10-0484 (D. Del.)
|
Intuniv® (guanfacine hydrochloride extended-release tablets)
|
6,287,599
6,811,794
5,854,290
|
Shire will receive royalties when TWI makes—and Anchen sells—generic Intuniv tablets effective July 1, 2016;
Anchen is TWI’s authorized distributor, but is also authorized to occasionally sell generic Intuniv tablets and pay Shire royalties.
|
Genzyme Corp. v. Impax Labs., Inc., 09-0653 (D. Md.)
Genzyme Corp. v. Impax Labs., Inc., 09-0846 (D. Md.)
|
Renagel® (doxepin tablets)
Renvela® (doxepin tablets)
|
5,667,775
|
Impax may sell certain dosages of generic Renagel tablets and generic Renvela liquid treatments effective Sept. 16, 2014;
Impax may sell other dosages of generic Renagel tablets effective Mar. 16, 2014.
|